ArticleBasic & clinical pharmacology & toxicology2026
Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model.
Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus.Brain sciences · 2026Article
- Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model.Basic & clinical pharmacology & toxicology · 2026Article
- Elucidating the putative role of cannabigerol: a hypothesis-generating review of neuroinflammatory and neuroprotective mechanisms with implications for drug-resistant epilepsy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Current antiseizure therapy for epilepsy is only effective in about 70% of the patient population. Previous studies had shown that the addition of small amounts of tetrahydrocannabinol (THC) made cannabidiol (CBD) much more potent in the maximal electroshock seizure (MES) model. The psychotoxic effects of THC make it unsuitable as an antiseizure therapy. The current study investigated the effects of combining CBD with the non-psychotoxic cannabinoid cannabigerol (CBG) in the MES model in mice. Mice were administered (i.p.) CBD or CBG or a combination of both before undergoing the MES procedure. Dose-response and dose-toxicity curves were generated for each compound and combinations. It was found that CBG has antiseizure properties and that it potentiates the effects of CBD. By using a 1:1 ratio combination of CBD and CBG, the ED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.